| 20.09 14:54 | dpa-AFX: CHMP Recommends Expanded Approval Of Sanofi's Dupixent For Eosinophilic Esophagitis In Children |
| 20.09 14:30 | dpa-AFX: Sanofi Reports Positive Results From Phase 3 HERCULES Study Of Tolebrutinib In Multiple Sclerosis |
| 20.09 14:04 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Sanofi auf 'Neutral' - Ziel 100 Euro |
| 20.09 14:04 | dpa-AFX: JPMorgan belässt Sanofi auf 'Neutral' - Ziel 100 Euro |
| 20.09 14:02 | dpa-AFX: *SANOFI: DUPIXENT RECOMMENDED BY CHMP FOR EU APPROVAL TO TREAT EOSINOPHILIC ESOPHAGITIS IN KIDS |
| 20.09 13:45 | dpa-AFX: GNW-Adhoc: Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old |
| 20.09 11:30 | dpa-AFX: GNW-Adhoc: Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study |
| 17.09 08:15 | dpa-AFX: *CITIGROUP RAISES SANOFI PRICE TARGET TO 130 (125) EUR - 'BUY' |
| 17.09 08:15 | dpa-AFX: *CITIGROUP HEBT ZIEL FÜR SANOFI AUF 130 (125) EUR - 'BUY' |
| 16.09 14:21 | dpa-AFX: Sanofi To Offer BEYFORTUS Doses To Protect Babies During RSV Season |
| 16.09 14:03 | dpa-AFX: *SANOFI SAYS SHIPPING BEYFORTUS IN US TO HELP PROTECT BABIES AGAINST RSV DISEASE |
| 12.09 12:03 | dpa-AFX: Deutsche Bank Research belässt Sanofi auf 'Sell' - Ziel 85 Euro |
| 12.09 07:51 | Sanofi entwickelt mit Partnern Behandlung für seltene Krebsarten |
| 12.09 07:30 | dpa-AFX: Sanofi, RadioMedix, Orano Med Sign Deal For Next-Gen Radioligand Medicine For Rare Cancers |
| 12.09 07:16 | dpa-AFX: *SANOFI, RADIOMEDIX, ORANO MED ANNOUNCE LICENSING DEAL ON NEXT-GENERATION RADIOLIGAND MEDICINE FOR RARE CANCERS |
| 12.09 07:00 | dpa-AFX: GNW-Adhoc: Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers |
| 11.09 07:54 | Sanofi-Medikament Dupixent mit Studienerfolg bei Hautkrankheiten |
| 11.09 07:28 | dpa-AFX: Sanofi, Regeneron: ADEPT Study Of Dupixent In Bullous Pemphigoid Meets Endpoints |
| 11.09 07:05 | dpa-AFX: GNW-Adhoc: Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU |
| 11.09 07:04 | dpa-AFX: *SANOFI SAYS ADEPT STUDY OF DUPIXENT IN BULLOUS PEMPHIGOID MEETS ENDPOINTS |
|
|
